Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Q4 Results Preview: Pfizer, Merck, Roche, Amgen, Novo, Lilly, AstraZeneca

Executive Summary

Leadership changes at Pfizer, immuno-oncology combination updates from Merck and Roche, and the potential for Novo Nordisk to make a new offer for Ablynx – plus other highlights from upcoming biopharma earnings calls.

Advertisement

Related Content

Merck Hits IO Bullseye With Keytruda Combo In First-line Lung Cancer
Novartis Finds All-Important Head Of Oncology Business At Pfizer
2018 Preparation: PD-1 Predictions And Commercialization Challenges
Roche's Tecentriq-Avastin Combo Improves PFS In Kidney Cancer Too
Roche Powers Forward With First-Line Tecentriq In Advanced NSCLC
European Nod For Roche’s Ocrevus Clouded By Patient Limitation
Amgen Focuses On Pipeline As Mature Products Face Declining Demand
New Drugs Shine But Biosimilars Blunt Roche Revenue Rise
Bladder Cancer Market Wide Open As Tecentriq Fails Confirmatory 2L Trial
Baricitinib Complete Response May Put Lilly/Incyte Behind IL-6 Blockers In RA

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100262

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel